chart ready to fly, page-6

If you think about it LANI has the potential to become the market leader in the anti-viral stockpiling market. This market has probably grown substantially from the previous USD6bn size. If they license the ROW it wouldn't take a very high royalty to justify a USD2bn market cap. If they can get annual sales of US1bn and a 15% royalty then that could justify a 10 buck price in certain market circumstances.

They still have Relenza and the rest of the pipeline which is also very exciting. A cure for the common cold (BTA798)! Talk about the blockbuster of the century.

Unless something unexpected happens I don't see why BTA can't hit $10. If they listed on the nasdaq it could happen sooner. Anyway, that's what I'm hoping for... I'm not selling a single share till I see the LANI row license and GSK increased production figures.